Immuneering's CEO walks us through the company's MEK data in pancreatic cancer, and explains the science behind 'deep cyclic inhibition'

Ben Zeskind describes the company's 9 month follow-up for atebimetinib + mGnP, which showed 86% overall survival and 53% progression free survival.

Episode metadata supplied by the publisher feed · Published Oct 9, 2025

Embed this episode

Attribution link and audio player

NOW PLAYING

Immuneering's CEO walks us through the company's MEK data in pancreatic cancer, and explains the science behind 'deep cyclic inhibition'

0:00 23:20

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Similar Episodes

No similar episodes found.

No similar podcasts found.

This episode is 23 minutes long.

This episode was published on October 9, 2025.

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!